Discontinue valsartan immediately and address the hyponatraemia and hypertension with alternative agents
The most appropriate initial management is to stop valsartan, given the strong temporal association between its initiation and the onset of chronic hyponatraemia, and to initiate combination antihypertensive therapy with agents from different classes that do not include ARBs.
Rationale for Stopping Valsartan
The temporal relationship is compelling: sodium was consistently normal (139-144 mmol/L) for years, remained 141 mmol/L immediately before valsartan initiation, then dropped to 133 mmol/L one month after starting the drug 1. This pattern, combined with persistent hypotonic hyponatraemia (serum osmolality 259 mOsm/kg) with inappropriately concentrated urine (227 mOsm/kg) despite preserved renal function, strongly implicates valsartan 1, 2. While ARB-associated hyponatraemia is rare, published cases demonstrate nearly identical biochemical profiles to this patient 2. The FDA label explicitly warns of hyponatraemia as a known adverse effect requiring monitoring 1.
The concurrent mild hyperkalaemia (5.4 mmol/L on 160 mg dose) further supports discontinuation, as ARBs predictably impair renal potassium excretion through aldosterone suppression 1. Although this patient had intermittent mild hyperkalaemia predating valsartan, the drug clearly amplified this tendency in a dose-dependent manner 3.
Alternative Antihypertensive Strategy
For stage 2 isolated systolic hypertension (systolic 190-204 mmHg, diastolic 68-80 mmHg), initiate combination therapy with a thiazide-type diuretic plus a dihydropyridine calcium channel blocker as a single-pill combination 4.
This recommendation is based on:
2025 AHA/ACC guidelines strongly recommend (Class 1, Level B-R) initiating two first-line agents of different classes, ideally as a single-pill combination, for stage 2 hypertension (SBP ≥140 mmHg) 4. With systolic pressures approaching 200 mmHg, this patient clearly meets criteria for dual therapy.
Thiazide diuretics are particularly effective for isolated systolic hypertension in older adults 5. In the ValVET trial of patients ≥70 years with systolic hypertension, hydrochlorothiazide monotherapy reduced systolic BP by 13.6 mmHg at 4 weeks 5.
Combining a dihydropyridine calcium channel blocker with a thiazide addresses the underlying arterial stiffness while avoiding the sodium and potassium disturbances associated with ARBs. The severe aortic atherosclerosis, markedly widened pulse pressure (132 mmHg), and elevated intrarenal resistive indices (0.92-0.96) all point to systemic arterial stiffness as the dominant pathophysiology.
The combination reduces side effects: thiazides may cause hypokalaemia while calcium channel blockers do not affect potassium, creating a balanced profile 4.
Managing the Hyponatraemia
Implement initial fluid restriction to 500-1000 mL/day with adequate dietary solute intake (salt and protein), and monitor sodium every 2-3 days 6.
For asymptomatic chronic hyponatraemia (current sodium 129-133 mmol/L), fluid restriction with adequate solute intake is first-line therapy 6. The patient's chronically low body weight (BMI 17) and limited dietary intake may contribute to low solute load, impairing free-water excretion 7.
If sodium fails to improve within 1-2 weeks after stopping valsartan and implementing fluid restriction, consider oral urea (15-30 g/day in divided doses) as second-line therapy 6. Urea is considered very effective and safe for SIADH-pattern hyponatraemia 6.
Avoid vaptans initially given the uncertain aetiology and risk of overcorrection 8. While vasopressin receptor antagonists increase sodium concentration (moderate certainty evidence), they carry a 67% increased risk of rapid correction and have uncertain effects on mortality and quality of life 8.
Addressing the Hyperkalaemia
The mild hyperkalaemia (5.4 mmol/L) should improve spontaneously after stopping valsartan 3, 1. Monitor potassium weekly for the first month.
If hyperkalaemia persists above 5.5 mmol/L after ARB discontinuation, ensure adequate dietary potassium restriction and consider adding a thiazide diuretic (which will already be part of the antihypertensive regimen and promotes kaliuresis) 3.
Do not down-titrate or discontinue disease-modifying therapy prematurely 3. However, in this case, valsartan is causing more harm than benefit given the severe hyponatraemia, and alternative antihypertensive agents are available.
Monitoring Plan
- Blood pressure: Check weekly until controlled to target <130/80 mmHg, then monthly 4
- Sodium: Every 2-3 days initially, then weekly once stable 6
- Potassium and creatinine: Weekly for 4 weeks, then monthly 1
- Ensure correction rate does not exceed 8-10 mmol/L in 24 hours to avoid osmotic demyelination syndrome 6
Excluding Secondary Causes
While the available workup has excluded renal artery stenosis, adrenal masses, and primary aldosteronism (given the hyperkalaemia), maintain vigilance for NF1-associated pheochromocytoma despite the atypical presentation 9, 10. The severe hypertension, though isolated systolic, warrants:
- Plasma or 24-hour urine fractionated metanephrines if not already obtained 9, 10
- Recognition that NF1-associated pheochromocytoma can present atypically with isolated metanephrine elevation or even hypotension 9
Common Pitfalls to Avoid
- Do not continue ARB therapy hoping the hyponatraemia will resolve spontaneously—the temporal relationship and persistent nature over 18 months make this unlikely 1, 2
- Do not combine an ACE inhibitor, ARB, and/or renin inhibitor—this is explicitly contraindicated (Class 3: Harm) due to increased adverse events without benefit 4
- Do not aggressively correct chronic hyponatraemia—gradual correction over days is safer than rapid normalization 6
- Do not attribute all findings to arterial stiffness alone—the rapid progression and NF1 diagnosis mandate exclusion of secondary causes including pheochromocytoma 9, 10